BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 11888095)

  • 21. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution.
    Wildemeersch D; Pylyser K; De Wever N; Pauwels P; Tjalma W
    Maturitas; 2007 Jun; 57(2):205-9. PubMed ID: 17227699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy.
    Suhonen S; Holmström T; Lähteenmäki P
    Acta Obstet Gynecol Scand; 1997 Feb; 76(2):145-50. PubMed ID: 9049288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women.
    Wildemeersch D; Janssens D; Schacht E; Pylyser K; de Wever N
    Gynecol Endocrinol; 2005 Jun; 20(6):336-42. PubMed ID: 16019384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.
    Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT
    Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.
    Sturdee DW; Ulrich LG; Barlow DH; Wells M; Campbell MJ; Vessey MP; Nielsen B; Anderson MC; Bragg AJ
    BJOG; 2000 Nov; 107(11):1392-400. PubMed ID: 11117768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy.
    Wildemeersch D; Schacht E; Wildemeersch P; Calleweart K; Pylyser K; De Wever N
    Maturitas; 2004 May; 48(1):65-70. PubMed ID: 15223110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial.
    MacLennan AH; MacLennan A; Wenzel S; Chambers HM; Eckert K
    Med J Aust; 1993 Jul; 159(2):102-6. PubMed ID: 8336583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
    Ross AH; Boyd ME; Colgan TJ; Ferenczy A; Fugere P; Lorrain J
    Obstet Gynecol; 1993 Nov; 82(5):773-9. PubMed ID: 8414325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal oestradiol gel in the treatment of the climacterium: a comparison with oral therapy.
    Hirvonen E; Lamberg-Allardt C; Lankinen KS; Geurts P; Wilén-Rosenqvist G
    Br J Obstet Gynaecol; 1997 Nov; 104 Suppl 16():19-25. PubMed ID: 9389779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study.
    Wildemeersch D; Schacht E
    Maturitas; 2000 Jul; 36(1):63-8. PubMed ID: 10989243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in post-menopausal women.
    Hirvonen E; Lipasti A; Mälkönen M; Kärkkäinen J; Nuntila J; Timonen H; Manninen V
    Maturitas; 1987 Apr; 9(1):69-79. PubMed ID: 2955205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrauterine release of levonorgestrel--a new way of adding progestogen in hormone replacement therapy.
    Andersson K; Mattsson LA; Rybo G; Stadberg E
    Obstet Gynecol; 1992 Jun; 79(6):963-7. PubMed ID: 1579323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, multicentre study comparing the clinical effects of two sequential estradiol-progestin combinations containing either desogestrel or norethisterone acetate in climacteric women with estrogen deficiency symptoms.
    Saure A; Hirvonen E; Milsom I; Christensen A; Damber MG
    Maturitas; 1996 May; 24(1-2):111-8. PubMed ID: 8794442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Läärä E; Pramila S; Kauppila A
    Maturitas; 1997 Apr; 26(3):211-7. PubMed ID: 9147353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential combined transdermal and oral postmenopausal hormone replacement therapies: effects on bleeding patterns and endometrial histology.
    Sendag F; Terek MC; Karadadas N
    Arch Gynecol Obstet; 2001 Nov; 265(4):209-13. PubMed ID: 11789748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A; Rutanen EM
    Maturitas; 1995 Nov; 22(3):255-62. PubMed ID: 8746884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy.
    Suhonen SP; Allonen HO; Lähteenmäki P
    Am J Obstet Gynecol; 1995 Feb; 172(2 Pt 1):562-7. PubMed ID: 7856686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women.
    Tilly-Kiesi M; Kahri J; Pyörälä T; Puolakka J; Luotola H; Lappi M; Lahdenperä S; Taskinen MR
    Atherosclerosis; 1997 Mar; 129(2):249-59. PubMed ID: 9105568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the effects of intrauterine progestin system and oral progestin on health-related quality of life and Kupperman index in hormone replacement therapy.
    Pirimoglu ZM; Ozyapi AG; Kars B; Buyukbayrak EE; Solak Y; Karsidag AY; Unal O; Turan MC
    J Obstet Gynaecol Res; 2011 Oct; 37(10):1376-81. PubMed ID: 21599801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women.
    Mc Manus J; Mc Eneny J; Thompson W; Young IS
    Atherosclerosis; 1997 Nov; 135(1):73-81. PubMed ID: 9395275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.